A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 gp41 core structure

Journal of Biomolecular Screening

Volumn 16, Issue 2, 2011, Pages 221-229

  Pang, Wei ^a   Wang, Rui Rui ^a   Gao, Yue Dong ^a   Yang, Liu Meng ^a   Sun, Yi ^a   Huang, Jing Fei ^a   Tien, Po ^b   Zheng, Yong Tang ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

C34 30a; enzyme linked immunosorbent assay; fusion inhibitor; GST HR121; HIV 1

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; PROTEIN SUBUNIT; SIFUVIRTIDE; ZIDOVUDINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; VIRUS CELL INTERACTION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GIANT CELLS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79951966908     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110393333     Document Type: Article

References (28)

1. Ni L., Gao GF, Tien P.: Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochem Biophys Res Commun 2005 ; 332: 831-836. (Pubitemid 40745188)
2. Freed EO, Martin MA: The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995 ; 270: 23883-23886.
3. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998 ; 93: 681-684. (Pubitemid 28257575)
4. Pang W., Tam SC, Zheng YT: Current peptide HIV type-1 fusion inhibitors. Antiviral Chem Chemother 2009 ; 20: 1-18.
5. Chan DC, Fass D., Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997 ; 89: 263-273. (Pubitemid 27199898)
6. Weissenhorn W., Dessen A., Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997 ; 387: 426-430. (Pubitemid 27227210)
7. Tan K., Liu J., Wang J., Shen S., Lu M.: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997 ; 94: 12303-12308. (Pubitemid 27492523)
8. Pang W., Wang RR, Yang LM, Liu CM, Tien P., Zheng YT: Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology 2008 ; 377: 80-87.
9. Zhu J., Zhang CW, Qi Y., Tien P., Gao GF: The fusion protein core of measles virus forms stable coiled-coil trimer. Biochem Biophys Res Commun 2002 ; 299: 897-902. (Pubitemid 36034571)
10. Wang RR, Yang LM, Wang YH, Pang W., Tam SC, Tien P.,, et al. Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 2009 ; 382: 540-544.
11. Liu S., Jing W., Cheung B., Lu H., Sun J., Yan X.,, et al. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J Biol Chem 2007 ; 282: 9612-9620. (Pubitemid 47104580)
12. Kliger Y., Gallo SA, Peisajovich SG, Munoz-Barroso I., Avkin S., Blumenthal R.,, et al. Mode of action of an antiviral peptide from HIV-1: inhibition at a post-lipid mixing stage. J Biol Chem 2001 ; 276: 1391-1397. (Pubitemid 32096570)
13. Liu S., Lu H., Niu J., Xu Y., Wu S., Jiang S.: Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005 ; 280: 11259-11273. (Pubitemid 40418432)
14. Wang RR, Wang Q., Ge ZM, Zheng YT: AGB, an acrosin inhibitor, blocks the entry of HIV-1 into cells. Reprod Contraception 2005 ; 25 (11). 241-246.
15. Bewley CA, Louis JM, Ghirlando R., Clore GM: Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002 ; 277: 14238-14245. (Pubitemid 34968038)
16. He Y., Liu S., Jing W., Lu H., Cai D., Chin DJ,, et al. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem 2007 ; 282: 25631-25639. (Pubitemid 47372795)
17. He Y., Xiao Y., Song H., Liang Q., Ju D., Chen X.,, et al. Design and evaluation of sifuvirtide: a novel HIV-1 fusion inhibitor. J Biol Chem 2008 ; 283: 11126-11134.
18. Huang JH, Lu L., Lu H., Chen X., Jiang S., Chen YH: Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. J Biol Chem 2007 ; 282: 6143-6152. (Pubitemid 47100832)
19. Lee-Huang S., Huang PL, Zhang D., Lee JW, Bao J., Sun Y.,, et al. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. Fusion [corrected] inhibition. Biochem Biophys Res Commun 2007 ; 354: 872-878. (Pubitemid 46216214)
20. Kahle KM, Steger HK, Root MJ Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PloS Pathog 2009 ; 5: e1000674.
21. Wang H., Qi Z., Guo A., Mao Q., Lu H., An X.,, et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother 2009 ; 53: 4987-4998.
22. Jiang S., Lin K., Zhang L., Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999 ; 80: 85-96. (Pubitemid 29248906)
23. Liu S., Boyer-Chatenet L., Lu H., Jiang S.: Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. J Biomol Screen 2003 ; 8: 685-693.
24. Jin BS, Lee WK, Ahn K., Lee MK, Yu YG: High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41. J Biomol Screen 2005 ; 10: 13-19.
25. Nishikawa H., Kodama E., Sakakibara A., Fukudome A., Izumi K., Oishi S.,, et al. Novel screening systems for HIV-1 fusion mediated by two extravirion heptad repeats of gp41. Antiviral Res 2008 ; 80: 71-76.
26. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS: Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999 ; 99: 103-115. (Pubitemid 29468634)
27. Dams G., Van Acker K., Gustin E., Vereycken I., Bunkens L., Holemans P.,, et al. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion. J Biomol Screen 2007 ; 12: 865-874. (Pubitemid 47340705)
28. Frey G., Rits-Volloch S., Zhang XQ, Schooley RT, Chen B., Harrison SC: Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci U S A 2006 ; 103: 13938-13943. (Pubitemid 44452961)